Neuroscience drug developer Seaport Therapeutics and blood clotting disorder biotech Hemab Therapeutics both filed for initial public offerings on Friday night. The filings mark the beginning of what could be a significant spring cohort for biotech IPOs. Another company, Kailera, is expected to price its offering soon.
The filings come as the biotech sector shows signs of renewed investor interest after a prolonged downturn. Public market debuts have been closely watched as indicators of broader market health for life sciences companies. Successful offerings could encourage other private biotechs to follow suit.